The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

Int J Impot Res. Jan-Feb 2007;19(1):55-61. doi: 10.1038/sj.ijir.3901497. Epub 2006 Jul 20.


The aim of this study was to determine, in an animal model, the effects of tadalafil on myocardial infarct size (IS), hemodynamics and regional myocardial blood flow after myocardial ischemia and reperfusion. Patients with erectile dysfunction (ED) often have risk factors for coronary artery disease. Tadalafil, a long-acting inhibitor of the enzyme phosphodiesterase-5 (PDE5), is used for the treatment of ED; there are no previous data regarding tadalafil in the setting of coronary artery occlusion (CAO). Sprague-Dawley male rats were treated with tadalafil or vehicle (10 mg/kg, by gastric gavage), 2 h before a 30 min CAO. Heart rate was comparable between tadalafil and control groups. Tadalafil reduced mean arterial pressure (P=0.009), systolic (P=0.035) and diastolic (P=0.009) blood pressures during ischemia/reperfusion. Tadalafil significantly reduced IS (42+/-2%) versus controls (54+/-3%) (P=0.006). For the first time, we showed that the PDE5 inhibitor, tadalafil, was well tolerated and cardioprotective in the setting of an experimental myocardial infarction, by substantially reducing ischemic cell death.

MeSH terms

  • Animals
  • Blood Pressure / drug effects
  • Carbolines / therapeutic use*
  • Constriction
  • Coronary Vessels
  • Heart Rate / drug effects
  • Male
  • Myocardial Infarction / drug therapy*
  • Myocardial Reperfusion Injury / prevention & control
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Potassium Channels / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Tadalafil


  • Carbolines
  • Phosphodiesterase Inhibitors
  • Potassium Channels
  • Tadalafil